Award-Winning Baseus Security X1 Pro: The World's First Smart AI Dual-Tracking Outdoor Security Camera, Now Crowdfunding on Kickstarter

LAS VEGAS, Oct. 16, 2025 /PRNewswire/ -- Baseus has always been at the forefront of innovative technologies and designs that uplift people and their lifestyles. This has led to several unique and advanced products throughout the years that prioritize comfort, safety, and simplicity. Now, Baseus is thrilled to announce the exceptional Baseus Security X1 Pro Outdoor Dual Camera, a revolutionary step in comprehensive and intelligent smart monitoring and safety.

The X1 Pro outdoor dual camera made its debut at the IFA 2025 event, where it was honored with the Honoree Award in the Smart Home Category and has already been recognized for several Top Tech awards. It is also a crowdfunding project on Kickstarter, enabling Baseus to broaden its marketing reach and refine product features for a stronger global presence.

Smart Al Dual-Tracking: The X1 Pro noticeably takes the title of being the world's first Smart AI Dual-Tracking Security Camera and uses dual independent 3K cameras for excellent visuals. With two 125° cameras that each feature 55° horizontal panning, you can ensure an ultra-wide view of your home and surroundings at the same time. With 300° maximum pan tracking Smart Patrol Mode, the camera effortlessly protects two yards at the same time, along with image custom stitching up to 180° available on the app.

Dual Independent Camera Tracking: Unlike a single-lens camera that only tracks one thing at a time, the X1 Pro uses its two AI-driven cameras to follow up to two subjects simultaneously, handing off capture to the other camera seamlessly to prevent blind spots and rotating independently at preset intervals to actively scan for potential threats for wide and consistent surveillance. With Dual Sentry and Patrol Mode, the two independent cameras work in tandem—each covering its own area—to deliver comprehensive, blind-spot-free protection. When placed on standby, both PIR sensors will remain alert, and once movement is detected, the cameras will automatically activate to track the subject within an 8m detection range and start recording through a clear split-screen.

Live Cross-Cam AI Tracking: Ensure unified and seamless capture with the X1 Pro, with cameras that work together to track motion from one to the other, providing you with accurate, detailed, and uninterrupted tracking paths.

3K Crystal-Clear Imaging: Capture every moment with 3K clarity and continuous detailed monitoring, day and night. With an 8m wide range, 8 times digital zoom, and 100LM spotlights, you'll always have the best view of your surroundings.

One Camera, Double the Value: At Baseus, we value your time and money. This is why the X1 Pro offers you the ultimate 2-in-1 security system that allows you to monitor your front and rear yards at the same time for overall protection at every angle.

20 Minutes of Sunlight for 24/7 Operation: Keep your security system running with clean, intelligent, and affordable solar energy. The X1 Pro outdoor dual camera uses an automatic sun-powered tracking system with a 120° adjustable solar panel that can detach for optimal sunlight absorption, offering you 3W solar charging and 24 hours of coverage after one 20-minute sunlight charge, seamlessly keeping the camera's built-in 150-day battery lifespan running.

Next-Level NeuraNex Technology 2.0: Take your monitoring to the next level with AI-powered detection that detects people, faces, vehicles, and pets, and only alerts for suspicious activity when notifications are enabled. This ensures fewer false alarms and notifications whenever the wind blows a little too hard. The Face Detection and Night Vision detection features are currently in beta testing and will be available in the final product after the launch.

No Cloud. No Subscription. Full Data Control: The X1 Pro outdoor dual camera keeps your data safe with AES + RSA dual encryption and EN 18031 privacy compliance while allowing you to store your data securely on local storage with no monthly subscription fees. The camera also supports a microSD card of up to 512GB for flexible storage expansion. As an exclusive benefit for this crowdfunding campaign, all current pledge packages will include a complimentary memory card.

IP65 Waterproof: Keep an eye out in every weather condition with the X1 Pro camera, which was engineered to withstand the toughest conditions with an IP65 rating, making it waterproof and resistant to extreme temperatures ranging from -20℃ to 50℃. The ETFE solar surface also ensures more than 95% UV light transmission and reliable weather resistance.

Seamless Installation: Easily set up and start using your X1 Pro outdoor camera anywhere with the patented three-axis flexible bracket, specially designed to tackle corner mounting challenges. This innovative design allows multiple viewing angles, ensuring optimal coverage even in hard-to-install spots like wall corners.

Smart Event Tagging and Search: The X1 Pro camera utilizes built-in AI tags to categorize each recorded event into a searchable timeline, enabling you to simply type in a keyword and instantly locate what you're looking for. The Smart Event Tagging and Search feature is also currently in beta testing and will only be available in the final product after launch. The camera is also compatible with Amazon Alexa, Android, and Google Assistant.

Smart App Control: Stay in control wherever you are with the Baseus Security app, where you can livestream your capture, view video replay, and get instant notifications.

Two-way Audio: Keep your line of communication open with your X1 Pro camera and transmit sound inside and outside of your home through the Baseus Security app. This allows you to easily speak to anyone at your door without leaving your home or family exposed.

The X1 Pro dual outdoor camera is an incredible milestone launch for Baseus as one of the company's first crowdfunding projects on Kickstarter. Apart from all of the camera's exceptional features and advanced technology, the launch also signifies a new direction in premium home security that can be accessible to all. Baseus is excited to introduce the future of home safety that prioritizes innovative features, proactive security, and user-centric values at every turn. For excellence that simplifies your home and lifestyle, choose Baseus today.

To reward early backers, the Baseus Security X1 Pro will launch on Kickstarter with exclusive Super Early Bird offers:

• One set with a 32GB card: $149.99 (regular $279.99), a savings of $130 (46.43% off)
• Two sets with a 32GB card: $289.98 (regular $559.98), saving you $270 (48.22% off).
• Four sets with a 32GB card: $579.96 (regular $1,119.96), saving a big $540 (48.22% off).

About Baseus

Founded in 2011, Baseus was born out of utmost care for users. The company embodies its slogan: Practical. Reliable. Base on User. This shows the pursuit of ultimate practicality to solve users' problems with outstanding design and fashionable appearances that also reflect reliability, high quality, and cost-effectiveness. Baseus delivers a variety of products - including Portable Chargers, Desktop Chargers, Wall Chargers, Wireless Earbuds, and Docking Stations. Chosen by 300 million users and providing 6 billion services, Baseus delivers over 100 million practical and aesthetic products each year, continuously enhancing users' sense of fulfillment. Join the Baseus family today to see a new world of technological innovation.

Media Contact:
Name: Baseus PR Team
Phone: +1 (213) 512-7063
Email: pr@baseus.com
Baseus Technology (HK) Co., Ltd
Baseus Official Website: https://www.baseus.com/

LAS VEGAS, Oct. 16, 2025 /PRNewswire/ -- Baseus has always been at the forefront of innovative technologies and designs that uplift people and their lifestyles. This has led to several unique and advanced products throughout the years that prioritize comfort, safety, and simplicity. Now, Baseus is thrilled to announce the exceptional Baseus Security X1 Pro Outdoor Dual Camera, a revolutionary step in comprehensive and intelligent smart monitoring and safety.

The X1 Pro outdoor dual camera made its debut at the IFA 2025 event, where it was honored with the Honoree Award in the Smart Home Category and has already been recognized for several Top Tech awards. It is also a crowdfunding project on Kickstarter, enabling Baseus to broaden its marketing reach and refine product features for a stronger global presence.

Smart Al Dual-Tracking: The X1 Pro noticeably takes the title of being the world's first Smart AI Dual-Tracking Security Camera and uses dual independent 3K cameras for excellent visuals. With two 125° cameras that each feature 55° horizontal panning, you can ensure an ultra-wide view of your home and surroundings at the same time. With 300° maximum pan tracking Smart Patrol Mode, the camera effortlessly protects two yards at the same time, along with image custom stitching up to 180° available on the app.

Dual Independent Camera Tracking: Unlike a single-lens camera that only tracks one thing at a time, the X1 Pro uses its two AI-driven cameras to follow up to two subjects simultaneously, handing off capture to the other camera seamlessly to prevent blind spots and rotating independently at preset intervals to actively scan for potential threats for wide and consistent surveillance. With Dual Sentry and Patrol Mode, the two independent cameras work in tandem—each covering its own area—to deliver comprehensive, blind-spot-free protection. When placed on standby, both PIR sensors will remain alert, and once movement is detected, the cameras will automatically activate to track the subject within an 8m detection range and start recording through a clear split-screen.

Live Cross-Cam AI Tracking: Ensure unified and seamless capture with the X1 Pro, with cameras that work together to track motion from one to the other, providing you with accurate, detailed, and uninterrupted tracking paths.

3K Crystal-Clear Imaging: Capture every moment with 3K clarity and continuous detailed monitoring, day and night. With an 8m wide range, 8 times digital zoom, and 100LM spotlights, you'll always have the best view of your surroundings.

One Camera, Double the Value: At Baseus, we value your time and money. This is why the X1 Pro offers you the ultimate 2-in-1 security system that allows you to monitor your front and rear yards at the same time for overall protection at every angle.

20 Minutes of Sunlight for 24/7 Operation: Keep your security system running with clean, intelligent, and affordable solar energy. The X1 Pro outdoor dual camera uses an automatic sun-powered tracking system with a 120° adjustable solar panel that can detach for optimal sunlight absorption, offering you 3W solar charging and 24 hours of coverage after one 20-minute sunlight charge, seamlessly keeping the camera's built-in 150-day battery lifespan running.

Next-Level NeuraNex Technology 2.0: Take your monitoring to the next level with AI-powered detection that detects people, faces, vehicles, and pets, and only alerts for suspicious activity when notifications are enabled. This ensures fewer false alarms and notifications whenever the wind blows a little too hard. The Face Detection and Night Vision detection features are currently in beta testing and will be available in the final product after the launch.

No Cloud. No Subscription. Full Data Control: The X1 Pro outdoor dual camera keeps your data safe with AES + RSA dual encryption and EN 18031 privacy compliance while allowing you to store your data securely on local storage with no monthly subscription fees. The camera also supports a microSD card of up to 512GB for flexible storage expansion. As an exclusive benefit for this crowdfunding campaign, all current pledge packages will include a complimentary memory card.

IP65 Waterproof: Keep an eye out in every weather condition with the X1 Pro camera, which was engineered to withstand the toughest conditions with an IP65 rating, making it waterproof and resistant to extreme temperatures ranging from -20℃ to 50℃. The ETFE solar surface also ensures more than 95% UV light transmission and reliable weather resistance.

Seamless Installation: Easily set up and start using your X1 Pro outdoor camera anywhere with the patented three-axis flexible bracket, specially designed to tackle corner mounting challenges. This innovative design allows multiple viewing angles, ensuring optimal coverage even in hard-to-install spots like wall corners.

Smart Event Tagging and Search: The X1 Pro camera utilizes built-in AI tags to categorize each recorded event into a searchable timeline, enabling you to simply type in a keyword and instantly locate what you're looking for. The Smart Event Tagging and Search feature is also currently in beta testing and will only be available in the final product after launch. The camera is also compatible with Amazon Alexa, Android, and Google Assistant.

Smart App Control: Stay in control wherever you are with the Baseus Security app, where you can livestream your capture, view video replay, and get instant notifications.

Two-way Audio: Keep your line of communication open with your X1 Pro camera and transmit sound inside and outside of your home through the Baseus Security app. This allows you to easily speak to anyone at your door without leaving your home or family exposed.

The X1 Pro dual outdoor camera is an incredible milestone launch for Baseus as one of the company's first crowdfunding projects on Kickstarter. Apart from all of the camera's exceptional features and advanced technology, the launch also signifies a new direction in premium home security that can be accessible to all. Baseus is excited to introduce the future of home safety that prioritizes innovative features, proactive security, and user-centric values at every turn. For excellence that simplifies your home and lifestyle, choose Baseus today.

To reward early backers, the Baseus Security X1 Pro will launch on Kickstarter with exclusive Super Early Bird offers:

• One set with a 32GB card: $149.99 (regular $279.99), a savings of $130 (46.43% off)
• Two sets with a 32GB card: $289.98 (regular $559.98), saving you $270 (48.22% off).
• Four sets with a 32GB card: $579.96 (regular $1,119.96), saving a big $540 (48.22% off).

About Baseus

Founded in 2011, Baseus was born out of utmost care for users. The company embodies its slogan: Practical. Reliable. Base on User. This shows the pursuit of ultimate practicality to solve users' problems with outstanding design and fashionable appearances that also reflect reliability, high quality, and cost-effectiveness. Baseus delivers a variety of products - including Portable Chargers, Desktop Chargers, Wall Chargers, Wireless Earbuds, and Docking Stations. Chosen by 300 million users and providing 6 billion services, Baseus delivers over 100 million practical and aesthetic products each year, continuously enhancing users' sense of fulfillment. Join the Baseus family today to see a new world of technological innovation.

Media Contact:
Name: Baseus PR Team
Phone: +1 (213) 512-7063
Email: pr@baseus.com
Baseus Technology (HK) Co., Ltd
Baseus Official Website: https://www.baseus.com/

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Award-Winning Baseus Security X1 Pro: The World's First Smart AI Dual-Tracking Outdoor Security Camera, Now Crowdfunding on Kickstarter

HIGHLIGHTS

• Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol.

Patient population

• With the SECuRE trial continuing to recruit, a total of nine participants who had evaluable data by the 25^th of November 2025 were included in the interim assessment by the SRC, with the majority of participants receiving at least two cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each by the data cut-off date.
• Seven participants received ⁶⁷Cu-SAR-bisPSMA and two participants were treated with a combination of ⁶⁷Cu-SAR-bisPSMA with enzalutamide.
• Most participants were heavily pre-treated (with 55.6% having received more than 5 previous anti-cancer regimens) and had bone metastasis (66.7%).

Safety

• The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable with most related adverse events (AEs) in the Cohort Expansion to date being Grade 1 or 2. The most common AEs were nausea and lymphopenia (observed in 33.3% of participants, for each AE).

Efficacy

• Six participants had at least two prostate specific antigen (PSA) results following ⁶⁷Cu-SAR-bisPSMA administration, with all showing a decrease in PSA. Of those, four participants (66.7%) thus far had a reduction of more than 50% in PSA (PSA50) and two participants (33.3%) had a reduction of more than 80% (PSA80).
• One participant who presented with bone metastasis at enrolment achieved undetectable PSA with no prostate cancer detected by computed tomography (CT) or bone scan following ⁶⁷Cu-SAR-bisPSMA treatment. The participant reported having excellent quality of life following the treatment.

Next Steps

• The SECuRE trial will continue enrolment into the Cohort Expansion Phase with planned completion of recruitment in 2026. Phase III registrational trial planning ongoing based on data generated to date.

SYDNEY, Jan. 15, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to share a number of updates on the SECuRE trial following an SRC meeting. The SRC has recommended that the trial continue with the Cohort Expansion Phase (Phase II) as planned with no modifications to the protocol. The interim results assessed by the SRC were collected from nine participants enrolled in the cohort that had evaluable data by the cut-off date of the 25^th of November 2025 and continue to show promising efficacy and a favourable safety profile of ⁶⁷Cu-SAR-bisPSMA.

The majority of the nine participants had bone metastasis at enrolment (66.7%) and received multiple lines of previous treatments (more than 5 previous anti-cancer regimens, 55.6%). Median PSA prior to ⁶⁷Cu-SAR-bisPSMA treatment was 18.9 ng/mL (range 1.5-30.2 ng/mL). Six out of these nine participants received at least 2 cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each, with two of them also receiving concomitant enzalutamide.

Of the nine participants included in this SRC analysis, six had at least two PSA results following their ⁶⁷Cu-SAR-bisPSMA treatment by the data cut-off date. Of these six participants, thus far four (66.7%) showed reductions in PSA of 50% or more (PSA50) and two (33.3%) showed reductions of 80% or more (PSA80).

The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable in the Cohort Expansion, with the majority of related AEs being Grade 1 or 2. The most common related AEs were nausea and lymphopenia (observed in three out of nine participants [33.3%], for each AE). The only AE that was Grade 3 or above was lymphopenia observed in three participants, some of whom had bone metastasis at baseline and/or had received multiple lines of therapy, including taxane and an investigational agent, prior to enrolment in the SECuRE study. There have been no overall renal toxicity or electrocardiogram (ECG) changes observed in these participants. In the combination enzalutamide arm, no new AEs (or worsening of AEs) related to ⁶⁷Cu-SAR-bisPSMA have been observed to date.

Trial participant with no detectable disease after 3 cycles of ⁶⁷Cu-SAR-bisPSMA

One of the participants in the Cohort Expansion was a 64-year-old man with bone metastases and baseline PSA of 5.4 ng/mL prior to entering the SECuRE study. Following his first cycle of ⁶⁷Cu-SAR-bisPSMA, this participant showed a dramatic 95.2% reduction in PSA. He went on to receive 2 more cycles of ⁶⁷Cu-SAR-bisPSMA and achieved undetectable PSA levels. In a follow-up bone scan and CT no metastatic disease was observed. This participant only exhibited mild (Grade 1) related AEs, most of which were gastrointestinal events, with no haematological or renal AEs observed. The participant reported having excellent quality of life following the treatment.

The interim data from this Phase II continues to confirm the favourable safety profile and promising efficacy seen in previous cohorts of the SECuRE trial^[1] and supports the continuation of the trial with the aim to progress to a registrational Phase III study.

Clarity's Executive Chairperson, Dr Alan Taylor, commented, "SAR-bisPSMA continues generating world-class data in both theranostic and diagnostic trials. The combination of the optimised dimer 'bis' structure with the benefits of copper isotopes, enabled by the proprietary sarcophagine technology, is proving to have created a product that is here to challenge the current treatment and diagnostic paradigms in radiopharmaceuticals.

"We have already seen a glimpse of the effects of ⁶⁷Cu-SAR-bisPSMA through our Dose Escalation cohorts with additional and similar data being generated in the Cohort Expansion phase, demonstrating once again excellent efficacy and safety results of ⁶⁷Cu-SAR-bisPSMA.

"All of the participants with evaluable data treated in the Phase II to date have shown declines in PSA, with the majority showing PSA decreases of more than 50% and mostly having only mild or moderate AEs. Most of these patients have been treated with more than 5 systemic treatment regiments and had bone metastasis prior to entering the SECuRE study. Although the number of participants with evaluable data to date is small, it is incredible to see yet another extraordinary case where a patient who had bone metastasis prior to entering the study achieved undetectable PSA following ⁶⁷Cu-SAR-bisPSMA treatment, with no disease observed by anatomical and molecular imaging at the last assessments. This participant only experienced mild, transient AEs, most being gastrointestinal, and has reported having excellent quality of life following the treatment.

"Importantly, the work we have undertaken during the Dose Escalation Phase is now continuing to provide a strong foundation for us as we look ahead at protocol development and dosing for our Phase III clinical trial and commercialisation. As the participant numbers continue to increase with the trial enrollment, we continue to see very promising responses over and over again, giving us more confidence about the future of this product and its potential for commercialisation in metastatic castration-resistant prostate cancer (mCRPC). With three Fast Track Designations for the SAR-bisPSMA product and positive interactions with the US Food and Drug Administration (FDA) to date, we are working towards bringing this agent to clinicians and their patients around the world through the entirety of the prostate cancer journey, from first diagnosis to late-stage disease. All of these indications, being imaging in pre-definitive therapy and biochemical recurrence, as well as therapy in mCRPC, are blockbuster markets individually for prostate-specific membrane antigen (PSMA) targeted products, with an estimated combined market value of approximately US$10-15 billion by 2030. We are committed to continuing the development of this product, aiming to bring improved diagnostic and treatment options for prostate cancer in various stages of their disease."

About the SECuRE trial

The SECuRE trial (NCT04868604)^[2] is a Phase I/IIa theranostic trial for identification and treatment of participants with PSMA-expressing mCRPC using ⁶⁴Cu/⁶⁷Cu-SAR-bisPSMA. ⁶⁴Cu-SAR-bisPSMA is used to visualise PSMA-expressing lesions and select candidates for subsequent ⁶⁷Cu-SAR-bisPSMA therapy. The trial is a multi-centre, single arm, dose escalation study with a cohort expansion involving approximately 54 participants in the US. The overall aim of the trial is to determine the safety and efficacy of ⁶⁷Cu-SAR-bisPSMA for the treatment of prostate cancer.

The SECuRE trial consists of the Dose Escalation (Phase I) and Cohort Expansion (Phase II) Phases. Based on the data from the Dose Escalation Phase, which demonstrated a favourable safety profile and efficacy of ⁶⁷Cu-SAR-bisPSMA, the SECuRE trial progressed to the Cohort Expansion (Phase II) at an 8 GBq dose level as per the SRC recommendation (up to 6 cycles per patient in total)^[3].

Cohort 2 of the Dose Escalation phase of the trial, where participants were dosed with 8 GBq of ⁶⁷Cu-SAR-bisPSMA, demonstrated a very low rate of related AEs while all three participants achieved PSA declines of 80% or more (PSA80)^[1]. The Dose Escalation Phase also showed high PSA response rates of the mCRPC in the pre-chemotherapy setting with a favourable safety profile: 92% of pre-chemotherapy participants (12/13) demonstrated PSA drops greater than 35%, PSA reductions greater than 50% were reached in 61.5% (8/13) of participants, and reductions of 80% or more were achieved in 46.2% (6/13) of participants^[1]. These results supported the progress of the trial to its Cohort Expansion Phase using 8 GBq multi-dose in participants who had not received chemotherapy in the mCRPC setting.

Recruitment is currently ongoing into the Cohort Expansion Phase which will include 24 participants. A subset of participants will be treated with the combination of 8 GBq of ⁶⁷Cu-SAR-bisPSMA with enzalutamide (androgen receptor pathway inhibitor [ARPI]), in line with the positive results from the Enza-p trial^[4] and previous discussions with and advice from key global medical experts in the field of prostate cancer, including the Company's Clinical Advisory Board members, Prof Louise Emmett and Prof Oliver Sartor, as well as the SRC.

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word "bis", which reflects a novel approach of connecting two PSMA-targeting agents to Clarity's proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or ⁶⁴Cu) for imaging and copper-67 (Cu-67 or ⁶⁷Cu) for therapy.

⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA are unregistered products. The safety and efficacy of ⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide^[5]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the US and around 35,770 deaths from the disease^[6].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing TCTs based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact: